OPEN APP
Home >Companies >Cipla to launch generic version of Hepatitis C drug Sovaldi
The announcement follows a non-exclusive licensing agreement between Cipla and Gilead in September. Photo: HT
The announcement follows a non-exclusive licensing agreement between Cipla and Gilead in September. Photo: HT

Cipla to launch generic version of Hepatitis C drug Sovaldi

The drug will be sold in India under the brand name 'Hepcvir'

New Delhi: Cipla Ltd on Wednesday said it will introduce a generic version of Gilead Science’s blockbuster Hepatitis C drug Sovaldi.

The drug will be sold in India by Cipla under the brand name ‘Hepcvir’. The announcement follows a non-exclusive licensing agreement between Cipla and Gilead in September.

It is estimated that 12-18 million people in India are infected by the virus.

US drug maker Gilead Sciences Inc. has licensed hepatitis C drug Sovaldi to seven Indian generic companies, including Cipla, to make and sell a low-cost version of the medicine in 91 developing countries.

Under the non-exclusive licensing agreement, Cipla is allowed to set its own price for its version of the drug, and will pay a royalty on sales to Gilead. Sovaldi, whose generic name is Sofosbuvir, was introduced in the US in December.

Though it is considered to be the most effective medication to treat hepatitis C, Sovaldi was not easily accessible to patients because of its steep price—at least $1,000 a pill.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout